1
|
Blitzer GC, Paz C, Glassey A, Ganz OR, Giri J, Pennati A, Meyers RO, Bates AM, Nickel KP, Weiss M, Morris ZS, Mattison RJ, McDowell KA, Croxford E, Chappell RJ, Glazer TA, Rogus-Pulia NM, Galipeau J, Kimple RJ. Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia. Radiother Oncol 2024; 192:110093. [PMID: 38224919 PMCID: PMC10922976 DOI: 10.1016/j.radonc.2024.110093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/17/2024]
Abstract
PURPOSE Salivary dysfunction is a significant side effect of radiation therapy for head and neck cancer (HNC). Preliminary data suggests that mesenchymal stromal cells (MSCs) can improve salivary function. Whether MSCs from HNC patients who have completed chemoradiation are functionally similar to those from healthy patients is unknown. We performed a pilot clinical study to determine whether bone marrow-derived MSCs [MSC(M)] from HNC patients could be used for the treatment of RT-induced salivary dysfunction. METHODS An IRB-approved pilot clinical study was undertaken on HNC patients with xerostomia who had completed treatment two or more years prior. Patients underwent iliac crest bone marrow aspirate and MSC(M) were isolated and cultured. Culture-expanded MSC(M) were stimulated with IFNγ and cryopreserved prior to reanimation and profiling for functional markers by flow cytometry and ELISA. MSC(M) were additionally injected into mice with radiation-induced xerostomia and the changes in salivary gland histology and salivary production were examined. RESULTS A total of six subjects were enrolled. MSC(M) from all subjects were culture expanded to > 20 million cells in a median of 15.5 days (range 8-20 days). Flow cytometry confirmed that cultured cells from HNC patients were MSC(M). Functional flow cytometry demonstrated that these IFNγ-stimulated MSC(M) acquired an immunosuppressive phenotype. IFNγ-stimulated MSC(M) from HNC patients were found to express GDNF, WNT1, and R-spondin 1 as well as pro-angiogenesis and immunomodulatory cytokines. In mice, IFNγ-stimulated MSC(M) injection after radiation decreased the loss of acinar cells, decreased the formation of fibrosis, and increased salivary production. CONCLUSIONS MSC (M) from previously treated HNC patients can be expanded for auto-transplantation and are functionally active. Furthermore IFNγ-stimulated MSC(M) express proteins implicated in salivary gland regeneration. This study provides preliminary data supporting the feasibility of using autologous MSC(M) from HNC patients to treat RT-induced salivary dysfunction.
Collapse
Affiliation(s)
- Grace C Blitzer
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Cristina Paz
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Annemarie Glassey
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Olga R Ganz
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Jayeeta Giri
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Andrea Pennati
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Ross O Meyers
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Amber M Bates
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Kwangok P Nickel
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Marissa Weiss
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Zachary S Morris
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Ryan J Mattison
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Kimberly A McDowell
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Emma Croxford
- Department of Biostatistics and Medical Informatics, 610 Walnut Street, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53726 USA
| | - Richard J Chappell
- Department of Biostatistics and Medical Informatics, 610 Walnut Street, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53726 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Tiffany A Glazer
- Department of Surgery, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Nicole M Rogus-Pulia
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; Geriatric Research Education and Clinical Center, 2500 Overlook Terrace, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705 USA
| | - Jacques Galipeau
- Department of Medicine, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA
| | - Randall J Kimple
- Department of Human Oncology, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA; UW Carbone Cancer Center, 600 Highland Ave, University of Wisconsin, School of Medicine and Public Health, Madison, WI 53705 USA.
| |
Collapse
|
2
|
Ringer SK, Schmid A, Weiss M, Ohlerth S, Spielmann N, Clausen NG. Non-surgical external jugular vein catheterization using an ear vein access in piglets. Lab Anim 2023; 57:642-649. [PMID: 37077144 DOI: 10.1177/00236772231167224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
The objective of this study was to investigate the feasibility of external jugular vein catheterization through an ear vein in piglets. Forty-six sevoflurane-midazolam anaesthetized piglets were included. External jugular vein catheterization was conducted through the ear vein using the Seldinger technique. Part 1 (n = 27): optimal puncture site was based on the deltoid tuberosity as a landmark to reach the external jugular vein. The final position of the catheter was verified in 25 piglets using computer tomography. Catheterization time was recorded and patency of the catheter assessed by repeated blood sampling for up to 4 h. Part 2 (n = 19): ear vein catheterization was without taking into account any landmarks. Functionality for blood sampling was evaluated as described in part 1. Catheter advancement was possible in 25/27 and 18/19 piglets in parts 1 and 2, respectively. Median (range) time required for successful catheterization was 1.95 (1-10) min (n = 38). The deltoid tuberosity was a good landmark to reach the external jugular vein. But blood sampling was also possible through catheters ending slightly cranial to the external jugular vein. Despite successful catheter advancement, blood sampling was not possible from one catheter in each part of the study (total: two piglets). One of these catheters presented luminal damage, while the other one presented as normal after being removed from the animal. Summarizing, central vein catheterization through the ear vein was feasible in 93.5% and repeated blood sampling was possible in 89.1% of the piglets (n = 46).
Collapse
Affiliation(s)
- S K Ringer
- Section Anaesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty University of Zurich, Switzerland
| | - A Schmid
- Section Anaesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty University of Zurich, Switzerland
| | - M Weiss
- Department of Anaesthesia, University Children's Hospital Zurich, Switzerland
- Children's Research Centre, University Children's Hospital of Zurich, University of Zurich, Switzerland
| | - S Ohlerth
- Clinic of Diagnostic Imaging, Department of Clinical Diagnostics and Services, Vetsuisse Faculty University of Zurich, Switzerland
| | - N Spielmann
- Department of Anaesthesia, University Children's Hospital Zurich, Switzerland
- Children's Research Centre, University Children's Hospital of Zurich, University of Zurich, Switzerland
| | - N G Clausen
- Department of Anaesthesia, University Children's Hospital Zurich, Switzerland
- Children's Research Centre, University Children's Hospital of Zurich, University of Zurich, Switzerland
- Department of Anaesthesiology and Intensive Care, Odense University Hospital, Denmark
| |
Collapse
|
3
|
Denke C, Jaschinski U, Riessen R, Bercker S, Spies C, Ragaller M, Weiss M, Dey K, Michalsen A, Briegel J, Pohrt A, Sprung CL, Avidan A, Hartog CS. End-of-life practices in 11 German intensive care units : Results from the ETHICUS-2 study. Med Klin Intensivmed Notfmed 2023; 118:663-673. [PMID: 36169693 PMCID: PMC10624715 DOI: 10.1007/s00063-022-00961-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 08/09/2022] [Accepted: 08/30/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND End-of-life care is common in German intensive care units (ICUs) but little is known about daily practice. OBJECTIVES To study the practice of end-of-life care. METHODS Prospectively planned, secondary analysis comprising the German subset of the worldwide Ethicus‑2 Study (2015-2016) including consecutive ICU patients with limitation of life-sustaining therapy or who died. RESULTS Among 1092 (13.7%) of 7966 patients from 11 multidisciplinary ICUs, 967 (88.6%) had treatment limitations, 92 (8.4%) died with failed CPR, and 33 (3%) with brain death. Among patients with treatment limitations, 22.3% (216/967) patients were discharged alive from the ICU. More patients had treatments withdrawn than withheld (556 [57.5%] vs. 411 [42.5%], p < 0.001). Patients with treatment limitations were older (median 73 years [interquartile range (IQR) 61-80] vs. 68 years [IQR 54-77]) and more had mental decision-making capacity (12.9 vs. 0.8%), advance directives (28.6 vs. 11.2%), and information about treatment wishes (82.7 vs 33.3%, all p < 0.001). Physicians reported discussing treatment limitations with patients with mental decision-making capacity and families (91.3 and 82.6%, respectively). Patient wishes were unknown in 41.3% of patients. The major reason for decision-making was unresponsiveness to maximal therapy (34.6%). CONCLUSIONS Treatment limitations are common, based on information about patients' wishes and discussion between stakeholders, patients and families. However, our findings suggest that treatment preferences of nearly half the patients remain unknown which affects guidance for treatment decisions.
Collapse
Affiliation(s)
- C Denke
- Department of Anaesthesiology and Operative Intensive Care Medicine, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
| | - U Jaschinski
- Department of Anesthesiology and Critical Care, Medicine, University Hospital Augsburg, Augsburg, Germany
| | - R Riessen
- Department of Internal Medicine, Medical Intensive Care Unit, Universitätsklinikum Tübingen, Tübingen, Germany
| | - S Bercker
- Department of Anaesthesiology and Intensive, Care, University of Leipzig Medical Centre, Leipzig, Germany
| | - C Spies
- Department of Anaesthesiology and Operative Intensive Care Medicine, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
| | - M Ragaller
- Technical University Dresden, Department, of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
| | - M Weiss
- Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Ulm, Ulm, Germany
| | - K Dey
- Department of Anesthesiology and Intensive Care Medicine, Hospital of the Bundeswehr Berlin, Berlin, Germany
| | - A Michalsen
- Department of Anesthesiology, Critical Care, Emergency, Medicine, and Pain Therapy, Konstanz Hospital, Konstanz, Germany
| | - J Briegel
- Klinik für Anästhesiologie, LMU Klinikum München, Munich, Germany
| | - A Pohrt
- Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany
| | - C L Sprung
- Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - A Avidan
- Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - C S Hartog
- Klinik Bavaria Kreischa, Kreischa, Germany.
- Department of Anesthesiology and Operative Intensive Care Medicine, Charité Universitätsmedizin Berlin; Campus Charité, Berlin, Germany.
| |
Collapse
|
4
|
Blitzer GC, Glazer T, Burr A, Gustafson S, Ganz O, Meyers R, McDowell KA, Nickel KP, Mattison RJ, Weiss M, Chappell R, Rogus-Pulia NM, Galipeau J, Kimple RJ. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia. Cytotherapy 2023; 25:1139-1144. [PMID: 37589639 PMCID: PMC10615723 DOI: 10.1016/j.jcyt.2023.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 07/07/2023] [Accepted: 07/25/2023] [Indexed: 08/18/2023]
Abstract
BACKGROUND AIMS Xerostomia, or the feeling of dry mouth, is a significant side effect of radiation therapy for patients with head and neck cancer (HNC). Preliminary data suggest that mesenchymal stromal/stem cells (MSCs) can improve salivary function. We performed a first-in-human pilot study of interferon gamma (IFNγ)-stimulated autologous bone marrow-derived MSCs, or MSC(M), for the treatment of radiation-induced xerostomia (RIX). Here we present the primary safety and secondary efficacy endpoints. METHODS A single-center pilot clinical trial was conducted investigating the safety and tolerability of autologous IFNγ-stimulated MSC(M). The study was conducted under an approved Food and Drug Administration Investigational New Drug application using an institutional review board-approved protocol (NCT04489732). Patients underwent iliac crest bone marrow aspirate and MSC(M) were isolated, cultured, stimulated with IFNγ and cryopreserved for later use. Banked cells were thawed and allowed to recover in culture before patients received a single injection of 10 × 106 MSC(M) into the right submandibular gland under ultrasound guidance. The primary objective was determination of safety and tolerability by evaluating dose-limiting toxicity (DLT). A DLT was defined as submandibular pain >5 on a standard 10-point pain scale or any serious adverse event (SAE) within 1 month after injection. Secondary objectives included analysis of efficacy as measured by salivary quantification and using three validated quality of life instruments. Quantitative results are reported as mean and standard deviation. RESULTS Six patients with radiation-induced xerostomia who had completed radiation at least 2 years previously (average 7.8 years previously) were enrolled in the pilot study. The median age was 71 (61-74) years. Five (83%) patients were male. Five patients (83%) were treated with chemoradiation and one patient (17%) with radiation alone. Grade 1 pain was seen in 50% of patients after submandibular gland injection; all pain resolved within 4 days. No patients reported pain 1 month after injection, with no SAE or other DLTs reported 1 month after injection. The analysis of secondary endpoints demonstrated a trend of increased salivary production. Three patients (50%) had an increase in unstimulated saliva at 1 and 3 months after MSC(M) injection. Quality of life surveys also showed a trend toward improvement. CONCLUSIONS Injection of autologous IFNγ-stimulated MSC(M) into a singular submandibular gland of patients with RIX is safe and well tolerated in this pilot study. A trend toward an improvement in secondary endpoints of salivary quantity and quality of life was observed. This first-in-human study provides support for further investigation into IFNγ-stimulated MSC(M) injected in both submandibular glands as an innovative approach to treat RIX and improve quality of life for patients with HNC.
Collapse
Affiliation(s)
- Grace C Blitzer
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
| | - Tiffany Glazer
- Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Adam Burr
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Sara Gustafson
- Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Olga Ganz
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Ross Meyers
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Kimberly A McDowell
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Kwangok P Nickel
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Ryan J Mattison
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Marissa Weiss
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Richard Chappell
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Nicole M Rogus-Pulia
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA
| | - Jacques Galipeau
- UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Randall J Kimple
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
| |
Collapse
|
5
|
Eckelmann BJ, Blitzer GC, Smilowitz JB, Trask D, Weiss M, Weber S, Abbott D, Varley P, Neuman H, Maloney JD, Hinshaw JL, Morris BA, Merfeld E, Howard SP, Bradley KA, Baschnagel AM, Bassetti MF, Hennessey DW, Morris Z. Initial Results of a Phase II Trial of Hypofractionated Radiation Therapy for Inoperable Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 2023; 117:S147-S148. [PMID: 37784374 DOI: 10.1016/j.ijrobp.2023.06.564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) For patients with soft tissue sarcoma (STS) who cannot or choose not to have surgery, radiation can provide local tumor control in both palliative and definitive settings. Conventionally fractionated radiation provides modest (< 50%) rates of local control (LC) for STS at 2 years. To our knowledge, no prospective studies to date have evaluated the safety and efficacy of dose-escalated hypofractionated radiation therapy as treatment of inoperable STS. We hypothesized that dose-escalated, hypofractionated radiation therapy (RT) for inoperable STS could achieve higher rates of LC than reported in trials of conventionally fractionated RT. MATERIALS/METHODS An IRB-approved single institution prospective phase II clinical trial of dose-escalated, hypofractionated RT as local control for STS was designed and completed planned accrual. Exclusion criteria included anti-cancer systemic therapy within the preceding two weeks. Patients underwent hypofractionated RT utilizing either CT-guided radiation (24, 50%) or MRI-guided radiation treatments (24, 50%). Data on patient characteristics, RT dose and fractionation, LC, toxicity, and overall survival (OS) was collected. The primary endpoint was local tumor control (stable, partial, or complete response according to RECIST) at 2-years after completion of radiation. Secondary endpoints were acute and late toxicity, rates of complete response, 5-year local tumor control, and progression-free and overall survival. Acute toxicity was graded on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale during treatment and at 3 months following RT. RESULTS Forty-eight patients were enrolled, 17 with non-metastatic localized disease and 31 with metastatic disease. Median patient age was 64. Twenty-five men and 23 women were treated. Ninety-six total lesions were treated (36 lung, 7 extremity, 37 abdominopelvic, 16 other). Radiation dose per fraction ranged from 6-12 Gy for a total of 1-12 fractions (median dose was 52.5 Gy in 6 fractions. Median patient follow-up is 8.6 months (range 1 - 36 months). Six patients (13%) did not complete initial 3-month follow-up imaging. Of the 40 patients who have undergone 3-month follow up imaging, 32 (80%) had stable disease, 5 (12.5%) had partial response, 0 had complete response, and 3 (7.5%) had disease progression. Median PFS was 17.2 months at time of last follow up. Median OS was 12.9 months at time of last follow up. Twenty-five patients (52%) experienced an acute toxicity likely or possibly related to radiation. Three (6%) patients experienced CTACE grade 3 or greater treatment-related toxicity (pain, weakness, decreased range of motion, dermatitis). CONCLUSION In this initial report of a prospective, single-institution clinical trial of hypofractionated RT for STS not undergoing resection, we report low rates of acute grade 3 or greater toxicity and high rates of tumor response. We will continue to follow these patients to assess late toxicity and durability of tumor control.
Collapse
Affiliation(s)
- B J Eckelmann
- Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - G C Blitzer
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | - J B Smilowitz
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | - D Trask
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | - M Weiss
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | - S Weber
- Department of Surgical Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - D Abbott
- Department of Surgical Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - P Varley
- Department of Surgical Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - H Neuman
- Department of Surgical Oncology, University of Wisconsin, Madison, WI
| | - J D Maloney
- University of Wisconsin, Department of Cardiothoracic Surgery, Madison, WI
| | - J L Hinshaw
- Department of Radiology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - B A Morris
- Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI
| | - E Merfeld
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - S P Howard
- Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - K A Bradley
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - A M Baschnagel
- Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - M F Bassetti
- Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | - D W Hennessey
- Department of Orthopedic and Rehabilitation, University of Wisconsin, Madison, WI
| | - Z Morris
- University of Wisconsin - Madison, Madison, WI
| |
Collapse
|
6
|
Weiss M, Holzer MT, Muehlensiepen F, Ignatyev Y, Fiehn C, Bauhammer J, Schmidt J, Schlüter S, Dihkan A, Scheibner D, Schneider U, Valor-Mendez L, Corte G, Gupta L, Chinoy H, Lundberg I, Cavagna L, Distler JHW, Schett G, Knitza J. Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey. Rheumatol Int 2023; 43:1925-1934. [PMID: 37452880 PMCID: PMC10435645 DOI: 10.1007/s00296-023-05372-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Accepted: 06/12/2023] [Indexed: 07/18/2023]
Abstract
Antisynthease syndrome (ASSD) is a rare, complex and understudied autoimmune disease. Internet-based studies can overcome barriers of traditional on-site research and are therefore very appealing for rare diseases. The aim of this study was to investigate patient-reported symptoms, diagnostic delay, symptoms, medical care, health status, working status, disease knowledge and willingness to participate in research of ASSD patients by conducting an international web-based survey. The multilingual questionnaire was created by an international group of rheumatologists and patients and distributed online. 236 participants from 22 countries completed the survey. 184/236 (78.0%) were female, mean age (SD) was 49.6 years (11.3) and most common antisynthetase antibody was Jo-1 (169/236, 71.6%). 79/236 (33.5%) reported to work full-time. Median diagnostic delay was one year. The most common symptom at disease onset was fatigue 159/236 (67.4%), followed by myalgia 130/236 (55.1%). The complete triad of myositis, arthritis and lung involvement verified by a clinician was present in 42/236 (17.8%) at disease onset and in 88/236 (37.3%) during the disease course. 36/236 (15.3%) reported to have been diagnosed with fibromyalgia and 40/236 (16.3%) with depression. The most reported immunosuppressive treatments were oral corticosteroids 179/236 (75.9%), followed by rituximab 85/236 (36.0%). 73/236 (30.9%) had received physiotherapy treatment. 71/236 (30.1%) reported to know useful online information sources related to ASSD. 223/236 (94.5%) were willing to share health data for research purposes once a year. Our results reiterate that internet-based research is invaluable for cooperating with patients to foster knowledge in rare diseases.
Collapse
Affiliation(s)
- M Weiss
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| | - M T Holzer
- III. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - F Muehlensiepen
- Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany
| | - Y Ignatyev
- Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany
| | - C Fiehn
- Praxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany
| | - J Bauhammer
- Praxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany
| | - J Schmidt
- Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany
- Department of Neurology and Pain Treatment, Center for Translational Medicine, Neuromuscular Center, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany
- Department of Neurology, Neuromuscular Center, University Medical Center, Göttingen, Germany
| | - S Schlüter
- Myositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany
| | - A Dihkan
- The Swedish Working Group for Myositis, The Swedish Rheumatism Association, Stockholm, Sweden
| | - D Scheibner
- Myositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany
| | - U Schneider
- Department of Rheumatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - L Valor-Mendez
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| | - G Corte
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| | - L Gupta
- Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK
- Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK
- Department of Rheumatology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
| | - H Chinoy
- Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK
- Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
| | - I Lundberg
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
- Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
| | - L Cavagna
- Rheumatology Division, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy
| | - J H W Distler
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| | - G Schett
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| | - J Knitza
- Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany
| |
Collapse
|
7
|
Blitzer GC, Glazer T, Gustafson S, Burr A, Mattison R, Ganz O, Meyers R, McDowell K, Weiss M, Nickel KP, Chappell RJ, Pulia N, Gallipeau J, Kimple RJ. A Pilot, First in Human Study of Autologous IFN-Gamma Stimulated Mesenchymal Stromal Cells for Treatment of Radiation-Induced Xerostomia. Int J Radiat Oncol Biol Phys 2023; 117:S152. [PMID: 37784385 DOI: 10.1016/j.ijrobp.2023.06.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There are no existing effective treatments for radiation-induced xerostomia (RIX), a common side effect of head and neck radiation. Mesenchymal stromal cells (MSCs) exhibit regenerative effects in multiple tissues and may represent an effective cell therapy for the treatment of RIX. Here we present the primary safety and secondary efficacy endpoints of a first-in-human pilot study of IFNγ-stimulated autologous bone marrow- derived MSCs [MSC(M)] for the treatment of RIX. MATERIALS/METHODS We conducted a single-center clinical trial investigating the safety and tolerability of autologous IFNγ-stimulated MSC(M). The study was conducted under an FDA-IND and approved by the local IRB. Patients underwent bone marrow aspiration, MSC(M) were then culture-expanded, stimulated with IFNγ, and cryopreserved. Banked IFNγ-stimulated MSC(M) were thawed, allowed to recover, and then 10 × 106 MSC(M) were injected transcutaneously via ultrasound guidance into one submandibular gland. The primary objective was safety and tolerability determined by dose-limiting toxicity (DLT) defined as submandibular pain > 5 on a standard 10-point pain scale or any serious adverse event (SAE) within one month after injection. Secondary objectives included analysis of efficacy as measured by salivary quantification and using 3 validated quality of life instruments. Quantitative results are reported as mean and standard deviation (SD). RESULTS Six radiation-induced xerostomia patients with head and neck cancer who had completed radiation at least 2 years earlier were enrolled. The median age was 71 (61-74) and 5 (83%) patients were male. Five patients (83%) were treated with chemoradiation and one patient (17%) with radiation alone. The average dose of radiation to the injected submandibular gland was 59.9 Gy. Three patients (50%) reported a pain score of 1 after submandibular gland injection, all pain resolved within 4 days. No patients reported pain 1 month after injection, with no SAEs or other DLTs reported 1 month after injection. The analysis of secondary endpoints demonstrated a trend of increased salivary production. The mean unstimulated saliva was 0.13 mL/min (SD 0.17) at baseline and increased to 0.14 mL/min (SD 0.12) at 1 month after injection and 0.19 mL/min (SD 0.21) at 3-months. Quality of life surveys also showed a trend towards improvement. CONCLUSION Injection of autologous IFNγ-stimulated MSC(M) into the submandibular gland of patients with RIX is safe and well tolerated. A trend towards an improvement in secondary endpoints of salivary quantity and quality of life was observed. This first-in-human pilot study provides support for further investigation into IFNγ-stimulated MSC(M) as an innovative, potentially curative, remedy to treat RIX. A phase I dose-escalation study injecting into bilateral submandibular glands is scheduled to begin accrual in the spring of 2023.
Collapse
Affiliation(s)
- G C Blitzer
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | - T Glazer
- University of Wisconsin, Madison, WI
| | | | - A Burr
- Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI
| | | | - O Ganz
- University of Wisconsin, Madison, WI
| | - R Meyers
- University of Wisconsin, Madison, WI
| | | | - M Weiss
- Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
| | | | - R J Chappell
- University of Wisconsin, Department of Statistics, Biostatistics, and Medical Informatics, Madison, WI
| | - N Pulia
- University of Wisconsin, Madison, WI
| | | | - R J Kimple
- Department of Human Oncology, University of Wisconsin, Madison, WI
| |
Collapse
|
8
|
Hammersen J, Birndt S, Döhner K, Reuken P, Stallmach A, Sauerbrey P, La Rosée F, Pfirrmann M, Fabisch C, Weiss M, Träger K, Bremer H, Russo S, Illerhaus G, Drömann D, Schneider S, La Rosée P, Hochhaus A. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia 2023; 37:1879-1886. [PMID: 37507425 PMCID: PMC10457200 DOI: 10.1038/s41375-023-01979-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 07/12/2023] [Accepted: 07/19/2023] [Indexed: 07/30/2023]
Abstract
Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still conflicting. We sought to evaluate efficacy and safety of the Janus Kinase 1/2 inhibitor ruxolitinib, employing the previously developed COVID-19 Inflammation Score (CIS) in a prospective multicenter open label phase II trial (NCT04338958). Primary objective was reversal of hyperinflammation (CIS reduction of ≥25% at day 7 in ≥20% of patients). In 184 patients with a CIS of ≥10 (median 12) ruxolitinib was commenced at an initial dose of 10 mg twice daily and applied over a median of 14 days (range, 2-31). On day 7, median CIS declined to 6 (range, 1-13); 71% of patients (CI 64-77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. Median cumulative dose was 272.5 mg/d. Treatment was well tolerated without any grade 3-5 adverse events related to ruxolitinib. Forty-four patients (23.9%) died, all without reported association to study drug. In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation.
Collapse
Affiliation(s)
- J Hammersen
- Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany
| | - S Birndt
- Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany
| | - K Döhner
- Universitätsklinikum Ulm, Klinik für Innere Medizin III, Hämatologie, Onkologie, Palliativmedizin, Rheumatologie und Infektionskrankheiten, Ulm, Germany
| | - P Reuken
- Universitätsklinikum Jena, Klinik für Innere Medizin IV, Gastroenterologie, Hepatologie, Infektiologie, Interdisziplinäre Endoskopie, Jena, Germany
| | - A Stallmach
- Universitätsklinikum Jena, Klinik für Innere Medizin IV, Gastroenterologie, Hepatologie, Infektiologie, Interdisziplinäre Endoskopie, Jena, Germany
| | - P Sauerbrey
- Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany
| | - F La Rosée
- Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - M Pfirrmann
- Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München, München, Germany
| | - C Fabisch
- Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany
| | - M Weiss
- Universitätsklinikum Ulm, Klinik für Anästhesiologie und Intensivmedizin, Ulm, Germany
| | - K Träger
- Universitätsklinikum Ulm, Klinik für Anästhesiologie und Intensivmedizin, Ulm, Germany
| | - H Bremer
- Schwarzwald-Baar Klinikum, Lungenzentrum Donaueschingen, Donaueschingen, Germany
| | - S Russo
- Schwarzwald-Baar Klinikum, Klinik für Anästhesiologie, Intensiv-, Notfall- und Schmerzmedizin, Villingen-Schwenningen, Germany
| | - G Illerhaus
- Klinikum Stuttgart, Klinik für Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin, Stuttgart, Germany
| | - D Drömann
- Universitätsklinikum Schleswig-Holstein, Medizinische Klinik III, Pulmologie, Lübeck, Germany
| | - S Schneider
- SRH Klinikum Gera, Klinik für Pneumologie/Infektiologie, Hämatologie/Onkologie, Rheumatologie, Gera, Germany
| | - P La Rosée
- Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II, Hämatologie, Onkologie, Immunologie, Infektiologie und Palliativmedizin, Villingen-Schwenningen, Germany
| | - A Hochhaus
- Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany.
| |
Collapse
|
9
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. First Dark Matter Search with Nuclear Recoils from the XENONnT Experiment. Phys Rev Lett 2023; 131:041003. [PMID: 37566859 DOI: 10.1103/physrevlett.131.041003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/22/2023] [Indexed: 08/13/2023]
Abstract
We report on the first search for nuclear recoils from dark matter in the form of weakly interacting massive particles (WIMPs) with the XENONnT experiment, which is based on a two-phase time projection chamber with a sensitive liquid xenon mass of 5.9 ton. During the (1.09±0.03) ton yr exposure used for this search, the intrinsic ^{85}Kr and ^{222}Rn concentrations in the liquid target are reduced to unprecedentedly low levels, giving an electronic recoil background rate of (15.8±1.3) events/ton yr keV in the region of interest. A blind analysis of nuclear recoil events with energies between 3.3 and 60.5 keV finds no significant excess. This leads to a minimum upper limit on the spin-independent WIMP-nucleon cross section of 2.58×10^{-47} cm^{2} for a WIMP mass of 28 GeV/c^{2} at 90% confidence level. Limits for spin-dependent interactions are also provided. Both the limit and the sensitivity for the full range of WIMP masses analyzed here improve on previous results obtained with the XENON1T experiment for the same exposure.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Bazyk
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E J Brookes
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | | | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Flierman
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - C Fuselli
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Guan
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N F Hood
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Lombardi
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - R Singh
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V H S Wu
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - Y Xing
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- INFN-Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, 44122 Ferrara, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
10
|
Aprile E, Abe K, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Pellegrini Q, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Pollmann TR, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Searching for Heavy Dark Matter near the Planck Mass with XENON1T. Phys Rev Lett 2023; 130:261002. [PMID: 37450817 DOI: 10.1103/physrevlett.130.261002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/07/2023] [Accepted: 06/07/2023] [Indexed: 07/18/2023]
Abstract
Multiple viable theoretical models predict heavy dark matter particles with a mass close to the Planck mass, a range relatively unexplored by current experimental measurements. We use 219.4 days of data collected with the XENON1T experiment to conduct a blind search for signals from multiply interacting massive particles (MIMPs). Their unique track signature allows a targeted analysis with only 0.05 expected background events from muons. Following unblinding, we observe no signal candidate events. This Letter places strong constraints on spin-independent interactions of dark matter particles with a mass between 1×10^{12} and 2×10^{17} GeV/c^{2}. In addition, we present the first exclusion limits on spin-dependent MIMP-neutron and MIMP-proton cross sections for dark matter particles with masses close to the Planck scale.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Bazyk
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E J Brookes
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | | | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Flierman
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - C Fuselli
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Guan
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N F Hood
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Lombardi
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Q Pellegrini
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - T R Pollmann
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - R Singh
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V H S Wu
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - Y Xing
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- INFN-Ferrara and Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, 44122 Ferrara, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
11
|
Weiss M, Assier H, Hotz C, Hua C, Thomas L, Wolkenstein P, Ingen-Housz-Oro S. Acute generalized exanthematous pustulosis: Clinico-biological profile and inducing drugs in 83 patients. J Eur Acad Dermatol Venereol 2023; 37:e776-e778. [PMID: 36734481 DOI: 10.1111/jdv.18940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Accepted: 02/01/2023] [Indexed: 02/04/2023]
Affiliation(s)
- M Weiss
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France
| | - H Assier
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - C Hotz
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - C Hua
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris est Créteil EpidermE, Créteil, France
| | - L Thomas
- Department of Pharmacovigilance, AP-HP, Henri-Mondor Hospital, Creteil University, Créteil, France
| | - P Wolkenstein
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris est Créteil EpidermE, Créteil, France
| |
Collapse
|
12
|
Dupree J, Dunn RL, Yan P, Suh D, Marsh EE, Dalton V, Norton EC, Weiss M. Impact of different legislative in-vitro fertilization coverage mandates on male infertility care. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00276-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
13
|
Boksán K, Dechant M, Weiss M, Hellwig A, Stemmler M. A meta-analysis on the effects of incarceration-based opioid substitution treatment. Med Sci Law 2023; 63:53-60. [PMID: 35934979 DOI: 10.1177/00258024221118971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: Opioid substitution treatment (OST) is a common treatment for individuals who use opioids; however, empirical evidence on the effects of OST during incarceration is scarce. Our aim was to conduct a meta-analysis on the effects of incarceration-based OST on substance use, treatment engagement post-release and re-incarceration. Method: We searched for studies on individuals who were incarcerated and treated with OST, compared to a comparison group. Studies were only included if they reported data post-release. Results: N = 15 studies met the inclusion criteria. We found less opioid use, less other drug use, higher treatment engagement post-release and less re-incarceration among treated individuals compared to the comparison group. Moderator analyses showed some influence of length of follow-up period and study quality. Conclusions: Incarceration-based OST reduces drug use, re-incarceration and leads to higher treatment engagement after release. More research is needed on the effects of incarceration-based OST on secondary outcomes (e.g. health and social integration) and on factors that moderate these effects.
Collapse
Affiliation(s)
- K Boksán
- Institute of Psychology, 9171Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - M Dechant
- Institute of Psychology, 9171Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - M Weiss
- Institute of Psychology, 9171Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - A Hellwig
- Institute of Psychology, 9171Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - M Stemmler
- Institute of Psychology, 9171Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
14
|
Weiss M, Nikisher B, Haran H, Tefft K, Adams J, Edwards JG. High throughput screen of small molecules as potential countermeasures to galactic cosmic radiation induced cellular dysfunction. Life Sci Space Res (Amst) 2022; 35:76-87. [PMID: 36336373 DOI: 10.1016/j.lssr.2022.06.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 05/23/2022] [Accepted: 06/16/2022] [Indexed: 06/16/2023]
Abstract
Space travel increases galactic cosmic ray exposure to flight crews and this is significantly elevated once travel moves beyond low Earth orbit. This includes combinations of high energy protons and heavy ions such as 56Fe or 16O. There are distinct differences in the biological response to low-energy transfer (x-rays) or high-energy transfer (High-LET). However, given the relatively low fluence rate of exposure during flight operations, it might be possible to manage these deleterious effects using small molecules currently available. Virtually all reports to date examining small molecule management of radiation exposure are based on low-LET challenges. To that end an FDA approved drug library (725 drugs) was used to perform a high throughput screen of cultured cells following exposure to galactic cosmic radiation. The H9c2 myoblasts, ES-D3 pluripotent cells, and Hy926 endothelial cell lines were exposed to a single exposure (75 cGy) using the 5-ion GCRsim protocol developed at the NASA Space Radiation Laboratory (NSRL). Following GCR exposure cells were maintained for up to two weeks. For each drug (@10µM), a hierarchical cumulative score was developed incorporating measures of mitochondrial and cellular function, oxidant stress and cell senescence. The top 160 scores were retested following a similar protocol using 1µM of each drug. Within the 160 drugs, 33 are considered to have an anti-inflammatory capacity, while others also indirectly suppressed pro-inflammatory pathways or had noted antioxidant capacity. Lead candidates came from different drug classes that included angiotensin converting enzyme inhibitors or AT1 antagonists, COX2 inhibitors, as well as drugs mediated by histamine receptors. Surprisingly, different classes of anti-diabetic medications were observed to be useful including sulfonylureas and metformin. Using a hierarchical decision structure, we have identified several lead candidates. That no one drug or even drug class was completely successful across all parameters tested suggests the complexity of managing the consequences of galactic cosmic radiation exposure.
Collapse
Affiliation(s)
- M Weiss
- Department of Physiology, New York Medical College, Valhalla, New York
| | - B Nikisher
- Department of Physiology, New York Medical College, Valhalla, New York
| | - H Haran
- Department of Physiology, New York Medical College, Valhalla, New York
| | - K Tefft
- Department of Physiology, New York Medical College, Valhalla, New York
| | - J Adams
- Department of Physiology, New York Medical College, Valhalla, New York
| | - J G Edwards
- Department of Physiology, New York Medical College, Valhalla, New York.
| |
Collapse
|
15
|
Holtdirk F, Zindler T, Mehnert A, Bültmann O, Weiss M, Mayer J, Meyer B, Specht A, Bröde P, Claus M, Watzl C, Cheng F. Digital health applications to support patients with breast cancer: Effects of two tailored, dialogue-based programs on quality of life. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01501-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Capelli C, Cardoso JMR, Cichon D, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Fulgione W, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Gardner R, Glade-Beucke R, Grandi L, Grigat J, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Paschos P, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Stephen J, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Search for New Physics in Electronic Recoil Data from XENONnT. Phys Rev Lett 2022; 129:161805. [PMID: 36306777 DOI: 10.1103/physrevlett.129.161805] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 09/21/2022] [Indexed: 06/16/2023]
Abstract
We report on a blinded analysis of low-energy electronic recoil data from the first science run of the XENONnT dark matter experiment. Novel subsystems and the increased 5.9 ton liquid xenon target reduced the background in the (1, 30) keV search region to (15.8±1.3) events/(ton×year×keV), the lowest ever achieved in a dark matter detector and ∼5 times lower than in XENON1T. With an exposure of 1.16 ton-years, we observe no excess above background and set stringent new limits on solar axions, an enhanced neutrino magnetic moment, and bosonic dark matter.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - J J Cuenca-García
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Di Giovanni
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Gardner
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - F Lombardi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - P Paschos
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - S Reichard
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Stephen
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Xu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
17
|
Schänzler VM, Riedel M, Riedel F, Strizek B, Gembruch U, Weiss M, Mustea A, Egger EK, Recker F. Erratum: PJ – EPAs und die Frauenheilkunde – Evaluation des Ist- und Soll-Zustands und dessen Diskrepanz. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/a-1969-6768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- VM Schänzler
- Universitätsklinikum Bonn, Klinik für Geburtshilfe und Pränatale Medizin, Bonn, Deutschland
| | - M Riedel
- Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - F Riedel
- Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
| | - B Strizek
- Universitätsklinikum Bonn, Klinik für Geburtshilfe und Pränatale Medizin, Bonn, Deutschland
| | - U Gembruch
- Universitätsklinikum Bonn, Klinik für Geburtshilfe und Pränatale Medizin, Bonn, Deutschland
| | - M Weiss
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - A Mustea
- Klinik für Gynäkologie und Gynäkologische Onkologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - EK Egger
- Klinik für Gynäkologie und Gynäkologische Onkologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - F Recker
- Universitätsklinikum Bonn, Klinik für Geburtshilfe und Pränatale Medizin, Bonn, Deutschland
| |
Collapse
|
18
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Gangi PD, Pede SD, Giovanni AD, Stefano RD, Diglio S, Elykov A, Farrell S, Ferella AD, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hiraide K, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Li I, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Ni K, Oberlack U, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Lavina LS, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Westermann J, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis JP, Laubenstein M, Nisi S. Material radiopurity control in the XENONnT experiment. Eur Phys J C Part Fields 2022; 82:599. [PMID: 35821975 PMCID: PMC9270421 DOI: 10.1140/epjc/s10052-022-10345-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 04/19/2022] [Indexed: 11/18/2022]
Abstract
The selection of low-radioactive construction materials is of the utmost importance for rare-event searches and thus critical to the XENONnT experiment. Results of an extensive radioassay program are reported, in which material samples have been screened with gamma-ray spectroscopy, mass spectrometry, and \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn emanation measurements. Furthermore, the cleanliness procedures applied to remove or mitigate surface contamination of detector materials are described. Screening results, used as inputs for a XENONnT Monte Carlo simulation, predict a reduction of materials background (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\sim $$\end{document}∼17%) with respect to its predecessor XENON1T. Through radon emanation measurements, the expected \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn activity concentration in XENONnT is determined to be 4.2 (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{+0.5}_{-0.7}$$\end{document}-0.7+0.5) \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\upmu $$\end{document}μBq/kg, a factor three lower with respect to XENON1T. This radon concentration will be further suppressed by means of the novel radon distillation system.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, NY 10027 USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Ahmed Maouloud
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Alfonsi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - F Arneodo
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands.,Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Bruno
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates.,SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - B Cimmino
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands.,Institute for Subatomic Physics, Utrecht University, Utrecht, The Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - J J Cuenca-García
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - A Di Giovanni
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy.,INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing, 100084 China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Hiraide
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan.,Institute for Advanced Research, Nagoya University, Nagoya, Aichi, 464-8601 Japan
| | - M Kobayashi
- Physics Department, Columbia University, New York, NY 10027 USA.,Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - A Kopec
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing, 100084 China
| | - F Lombardi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany.,LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal.,Coimbra Polytechnic-ISEC, 3030-199 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - A Manfredini
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - F Marignetti
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France.,Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501 Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501 Japan
| | - A Molinario
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - K Morå
- Physics Department, Columbia University, New York, NY 10027 USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - M Murra
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - D Ramírez García
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Reichard
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland.,Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Scotto Lavina
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany.,Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - P L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C Therreau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Westermann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C Wittweg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Z Xu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - J Ye
- Physics Department, Columbia University, New York, NY 10027 USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy.,INFN, Sez. di Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, via G. Saragat 1, Edificio C, 44122 Ferrara, Italy
| | - Y Zhang
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - T Zhu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J P Zopounidis
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | | | - M Laubenstein
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - S Nisi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| |
Collapse
|
19
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare J, Antochi V, Antón Martin D, Arneodo F, Baudis L, Baxter A, Bellagamba L, Bernard A, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso J, Cichon D, Cimmino B, Clark M, Colijn A, Conrad J, Cuenca-García J, Cussonneau J, D’Andrea V, Decowski M, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Farrell S, Ferella A, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang R, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes J, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, dos Santos J, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis J. Emission of single and few electrons in XENON1T and limits on light dark matter. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.022001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
20
|
Parakrama R, Sidiqi B, Demyan L, Pasha S, Pinto D, Zavadsky T, Zou X, Patruni S, Kapusta A, Standring O, Weiss M, Herman J, King D. P-10 Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient care and successful completion of NAT. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
21
|
Zizek D, Topalovic M, Stublar J, Mrak M, Jan M, Weiss M. Conduction system pacing in paediatric patients: a single centre experience. Europace 2022. [DOI: 10.1093/europace/euac053.412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Paediatric patients with conduction abnormalities are generally exposed to life-long dyssynchronous pacing from a very early age. Thus, preservation of cardiac function during chronic ventricular pacing is important. Conduction system pacing (CSP) with His bundle pacing (HBP) or left bundle branch pacing (LBBP) is an alternative method to standard right ventricular (RV) pacing that may preserve physiological ventricular activation and avoid potential pacing-induced cardiomyopathy (1). However, data on feasibility and safety of various CSP approaches in paediatric patients with or without congenital heart disease (CHD) is scarce and mainly relies on case studies (2-4).
Purpose
To assess feasibility and outcomes of different CSP techniques in paediatric patients.
Methods
Consecutive paediatric patients in whom CSP was attempted in our centre between November 2019 and December 2021 were analysed. Acute implant success rate, complications, fluoroscopy times, and CSP pacing parameters during follow-up were assessed.
To reduce radiation exposure, minimal fluoroscopy technique with three-dimensional (3D) electro-anatomical mapping (EAM) was also used in some cases. Geometry of right atrium and RV, along with mapping of His signal for HBP and potential LBBP sites in the RV septum were created using a decapolar catheter from the right femoral vein. Once relevant anatomy was obtained, HBP or LBBP was attempted using commercially available CSP tools. The pacing lead tip was visualised using the 3D EAM system. Transient fluoroscopy was used only for perpendicular placement of the sheath to the RV septum during LBBP, sheath removal, lead loop assessment to allow linear growth, and atrial lead placement.
Results
Six patients (100% female, age 9.3 ± 3.9 years, weight 41.8 ± 22.9 kg, baseline QRS 111.5 ± 6.3ms, CHD 50%, previous device 33%) with congenital complete AV block received CSP. One patient received HBP and 5 LBBP. The procedure was acutely successful in all patients (100%), pacing thresholds were low (0.56 ± 0.18V at 0.5ms) and there were no perioperative complications. During mean follow-up of 11.8 ± 7.8 months pacing parameters remained stable. However, significant rise of the pacing threshold (> 2.5V) was registered in the HBP patient, in whom lead revision was performed. Three-dimensional EAM was utilised in 3 patients (1 HBP, 2 LBBP). The use of minimal fluoroscopy technique with 3D EAM reduced fluoroscopy time (4.0, 3.2, 4.5 min vs. 9.5, 11.0, 8.0 min) without increasing procedural time (80, 70, 50 min vs. 110, 60, 75 min) compared to standard fluoroscopy technique.
Conclusion
Conduction system pacing is feasible and safe in paediatric patients with or without CHD. Additional utilisation of 3D EAM could reduce radiation exposure, without increasing procedural time. Future long-term studies should be considered to provide the ground for wider clinical adoption of CSP in paediatric population.
Collapse
Affiliation(s)
- D Zizek
- University Medical Centre Ljubljana, Department of Cardiology, Ljubljana, Slovenia
| | - M Topalovic
- University Medical Centre Ljubljana, Department of Paediatric Cardiology, Ljubljana, Slovenia
| | - J Stublar
- University Medical Centre Ljubljana, Department of Cardiology, Ljubljana, Slovenia
| | - M Mrak
- University Medical Centre Ljubljana, Department of Cardiology, Ljubljana, Slovenia
| | - M Jan
- University Medical Centre Ljubljana, Department of Cardiovascular Surgery, Ljubljana, Slovenia
| | - M Weiss
- University Medical Centre Ljubljana, Department of Cardiovascular Surgery, Ljubljana, Slovenia
| |
Collapse
|
22
|
De Oliveira Paludo A, Duarte Jr D, Kowalski A, Weiss M, Carvalhal E, Berger M, Berger A. Robotic assisted partial nephrectomy and mixed reality - first surgical planning experience with brainlab elements and magic leap 1. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)02308-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
23
|
Blitzer G, Yadav P, Bayouth J, Smilowitz J, Trask D, Weiss M, Weber S, Abbott D, Varley P, Neuman H, Maloney J, Hinshaw J, Morris B, Merfeld E, Howard S, Bradley K, Baschnagel A, Bassetti M, Parkes A, Hennessey D, Morris Z. Interim Results of a Phase II Trial on Hypofractionated Radiation Therapy for Inoperable Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Weiss M, Danese S, Ruiz K, Kjelstrom S, Buckley M, Leitenberger A, Bollmann-Jenkins M, Larson S, DeNittis A, Martinez D. A Survey of Breast Cancer Patients’ Use of Cannabis During Radiation Therapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021; 32:787-800. [PMID: 33746047 PMCID: PMC7972830 DOI: 10.1016/j.annonc.2021.02.024] [Citation(s) in RCA: 202] [Impact Index Per Article: 67.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 02/18/2021] [Accepted: 02/28/2021] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies. PATIENTS AND METHODS Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients). RESULTS A total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020) had worse outcomes than those diagnosed later. Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality. CONCLUSIONS Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anticancer therapies. CLINICAL TRIAL IDENTIFIER NCT04354701.
Collapse
Affiliation(s)
- P Grivas
- University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
| | - A R Khaki
- University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA; Stanford University, Stanford, USA
| | | | - B French
- Vanderbilt University Medical Center, Nashville, USA
| | - C Hennessy
- Vanderbilt University Medical Center, Nashville, USA
| | - C-Y Hsu
- Vanderbilt University Medical Center, Nashville, USA
| | - Y Shyr
- Vanderbilt University Medical Center, Nashville, USA
| | - X Li
- Vanderbilt University School of Medicine, Nashville, USA
| | | | - C A Painter
- Broad Institute, Cancer Program, Cambridge, USA
| | - S Peters
- Lausanne University, Lausanne, Switzerland
| | - B I Rini
- Vanderbilt University Medical Center, Nashville, USA
| | | | - S Mishra
- Vanderbilt University Medical Center, Nashville, USA
| | - D R Rivera
- Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, USA
| | - J D Acoba
- University of Hawaii Cancer Center, Honolulu, USA
| | - M Z Abidi
- University of Colorado School of Medicine, Aurora, USA
| | - Z Bakouny
- Dana-Farber Cancer Institute, Boston, USA
| | - B Bashir
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA
| | | | - S Berg
- Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, USA
| | | | - M A Bilen
- Winship Cancer Institute of Emory University, Atlanta, USA
| | - P Bindal
- Beth Israel Deaconess Medical Center, Boston, USA
| | - R Bishnoi
- University of Florida, Gainesville, USA
| | - N Bouganim
- McGill University Health Centre, Montréal, Canada
| | - D W Bowles
- University of Colorado School of Medicine, Aurora, USA
| | - A Cabal
- University of California San Diego, Moores Cancer Center, La Jolla, USA
| | - P F Caimi
- University Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA
| | - D D Chism
- Thompson Cancer Survival Center, Knoxville, USA
| | - J Crowell
- St. Elizabeth Healthcare, Edgewood, USA
| | - C Curran
- Dana-Farber Cancer Institute, Boston, USA
| | - A Desai
- Mayo Clinic Cancer Center, Rochester, USA
| | - B Dixon
- St. Elizabeth Healthcare, Edgewood, USA
| | - D B Doroshow
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
| | - E B Durbin
- Markey Cancer Center, University of Kentucky, Lexington, USA
| | - A Elkrief
- McGill University Health Centre, Montréal, Canada
| | - D Farmakiotis
- The Warren Alpert Medical School of Brown University, Providence, USA
| | - A Fazio
- Tufts Medical Center Cancer Center, Boston and Stoneham, USA
| | - L A Fecher
- University of Michigan Rogel Cancer Center, Ann Arbor, USA
| | - D B Flora
- St. Elizabeth Healthcare, Edgewood, USA
| | - C R Friese
- University of Michigan Rogel Cancer Center, Ann Arbor, USA
| | - J Fu
- Tufts Medical Center Cancer Center, Boston and Stoneham, USA
| | - S M Gadgeel
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA
| | - M D Galsky
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
| | - D M Gill
- Intermountain Healthcare, Salt Lake City, USA
| | | | - S Goyal
- George Washington University, Washington DC, USA
| | - P Grover
- University of Cincinnati Cancer Center, Cincinnati, USA
| | - S Gulati
- University of Cincinnati Cancer Center, Cincinnati, USA
| | - S Gupta
- Cleveland Clinic Taussig Cancer Institute, Cleveland, USA
| | | | | | - B Halmos
- Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA
| | - D J Hausrath
- Vanderbilt University School of Medicine, Nashville, USA
| | - J E Hawley
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA
| | - E Hsu
- Hartford HealthCare, Hartford, USA; University of Connecticut, Farmington, USA
| | - M Huynh-Le
- George Washington University, Washington DC, USA
| | - C Hwang
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA
| | - C Jani
- Mount Auburn Hospital, Cambridge, USA
| | | | - D B Johnson
- Vanderbilt University Medical Center, Nashville, USA
| | - A Kasi
- University of Kansas Medical Center, Kansas City, USA
| | - H Khan
- The Warren Alpert Medical School of Brown University, Providence, USA
| | - V S Koshkin
- University of California, San Francisco, San Francisco, USA
| | - N M Kuderer
- Advanced Cancer Research Group, LLC, Kirkland, USA
| | - D H Kwon
- University of California, San Francisco, San Francisco, USA
| | | | - A Li
- Baylor College of Medicine, Houston, USA
| | | | - C A Low
- Intermountain Healthcare, Salt Lake City, USA
| | | | - G H Lyman
- University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA
| | - R R McKay
- University of California San Diego, Moores Cancer Center, La Jolla, USA
| | - C McNair
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA
| | - H Menon
- Penn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, Hershey, USA
| | - R A Mesa
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA
| | - V Mico
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA
| | - D Mundt
- Advocate Aurora Health, Milwaukee, USA
| | - G Nagaraj
- Loma Linda University Cancer Center, Loma Linda, USA
| | - E S Nakasone
- University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA
| | - J Nakayama
- Case Western Reserve University, Cleveland, USA; University Hospitals Cleveland Medical Center, Cleveland, USA
| | - A Nizam
- Cleveland Clinic Taussig Cancer Institute, Cleveland, USA
| | - N L Nock
- University Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA
| | - C Park
- University of Cincinnati Cancer Center, Cincinnati, USA
| | - J M Patel
- Beth Israel Deaconess Medical Center, Boston, USA
| | - K G Patel
- University of California Davis Comprehensive Cancer Center, Sacramento, USA
| | - P Peddi
- Willis-Knighton Cancer Center, Shreveport, USA
| | - N A Pennell
- Cleveland Clinic Taussig Cancer Institute, Cleveland, USA
| | | | - M Puc
- Virtua Health, Marlton, USA
| | | | - M E Reeves
- Loma Linda University Cancer Center, Loma Linda, USA
| | - D Y Reuben
- Medical University of South Carolina, Charleston, USA
| | | | - R P Rosovsky
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | | | - M Salazar
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA
| | | | - G K Schwartz
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA
| | - M R Shah
- Rutgers Cancer Institute of New Jersey, New Brunswick, USA
| | - S A Shah
- Stanford University, Stanford, USA
| | - C Shah
- University of Florida, Gainesville, USA
| | - J A Shaya
- University of California San Diego, Moores Cancer Center, La Jolla, USA
| | - S R K Singh
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit, USA
| | - M Smits
- ThedaCare Regional Cancer Center, Appleton, USA
| | | | - D G Stover
- The Ohio State University, Columbus, USA
| | | | - S Subbiah
- Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, USA
| | - L Tachiki
- University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA
| | - E Tadesse
- Advocate Aurora Health, Milwaukee, USA
| | - A Thakkar
- Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA
| | - M D Tucker
- Vanderbilt University Medical Center, Nashville, USA
| | - A K Verma
- Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA
| | - D C Vinh
- McGill University Health Centre, Montréal, Canada
| | - M Weiss
- ThedaCare Regional Cancer Center, Appleton, USA
| | - J T Wu
- Stanford University, Stanford, USA
| | | | - Z Xie
- Mayo Clinic Cancer Center, Rochester, USA
| | - P P Yu
- Hartford HealthCare, Hartford, USA
| | - T Zhang
- Duke University, Durham, USA
| | - A Y Zhou
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA
| | - H Zhu
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
| | - L Zubiri
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - D P Shah
- Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA
| | - J L Warner
- Vanderbilt University Medical Center, Nashville, USA
| | - GdL Lopes
- University of Miami/Sylvester Comprehensive Cancer Center, Miami, USA
| |
Collapse
|
26
|
Mayo M, Karnik R, Klaus C, Sharma K, McDonald A, Walker DH, Weiss M. KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88
MT
LYMPHOMA MODELS. Hematol Oncol 2021. [DOI: 10.1002/hon.13_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M Mayo
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - R Karnik
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - C Klaus
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - K Sharma
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - A McDonald
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - D. H Walker
- Kymera Therapeutics, Research Watertown Massachusetts USA
| | - M Weiss
- Kymera Therapeutics, Research Watertown Massachusetts USA
| |
Collapse
|
27
|
Aprile E, Aalbers J, Agostini F, Alfonsi M, Althueser L, Amaro FD, Antochi VC, Angelino E, Angevaare JR, Arneodo F, Barge D, Baudis L, Bauermeister B, Bellagamba L, Benabderrahmane ML, Berger T, Breur PA, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Coderre D, Colijn AP, Conrad J, Cussonneau JP, Decowski MP, Depoian A, Di Gangi P, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Eurin G, Ferella AD, Fulgione W, Gaemers P, Gaior R, Rosso AG, Galloway M, Gao F, Grandi L, Garbini M, Hasterok C, Hils C, Hiraide K, Hoetzsch L, Hogenbirk E, Howlett J, Iacovacci M, Itow Y, Joerg F, Kato N, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Lin Q, Lindemann S, Lindner M, Lombardi F, Lopes JAM, López Fune E, Macolino C, Mahlstedt J, Manenti L, Manfredini A, Marignetti F, Undagoitia TM, Martens K, Masbou J, Masson D, Mastroianni S, Messina M, Miuchi K, Molinario A, Morå K, Moriyama S, Mosbacher Y, Murra M, Naganoma J, Ni K, Oberlack U, Odgers K, Palacio J, Pelssers B, Peres R, Pienaar J, Pizzella V, Plante G, Qin J, Qiu H, García DR, Reichard S, Rocchetti A, Rupp N, Santos JMFD, Sartorelli G, Šarčević N, Scheibelhut M, Schindler S, Schreiner J, Schulte D, Schumann M, Lavina LS, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Vargas M, Volta G, Wack O, Wang H, Wei Y, Weinheimer C, Weiss M, Wenz D, Westermann J, Wittweg C, Wulf J, Xu Z, Yamashita M, Ye J, Zavattini G, Zhang Y, Zhu T, Zopounidis JP. 222 Rn emanation measurements for the XENON1T experiment. Eur Phys J C Part Fields 2021; 81:337. [PMID: 34720714 PMCID: PMC8550029 DOI: 10.1140/epjc/s10052-020-08777-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 12/17/2020] [Indexed: 06/13/2023]
Abstract
The selection of low-radioactive construction materials is of utmost importance for the success of low-energy rare event search experiments. Besides radioactive contaminants in the bulk, the emanation of radioactive radon atoms from material surfaces attains increasing relevance in the effort to further reduce the background of such experiments. In this work, we present the 222 Rn emanation measurements performed for the XENON1T dark matter experiment. Together with the bulk impurity screening campaign, the results enabled us to select the radio-purest construction materials, targeting a 222 Rn activity concentration of 10 μ Bq / kg in 3.2 t of xenon. The knowledge of the distribution of the 222 Rn sources allowed us to selectively eliminate problematic components in the course of the experiment. The predictions from the emanation measurements were compared to data of the 222 Rn activity concentration in XENON1T. The final 222 Rn activity concentration of ( 4.5 ± 0.1 ) μ Bq / kg in the target of XENON1T is the lowest ever achieved in a xenon dark matter experiment.
Collapse
Affiliation(s)
| | - E. Aprile
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J. Aalbers
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - F. Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - M. Alfonsi
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L. Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F. D. Amaro
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
| | - V. C. Antochi
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - E. Angelino
- Department of Physics, INAF-Astrophysical Observatory of Torino, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - J. R. Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - F. Arneodo
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - D. Barge
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - L. Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - B. Bauermeister
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - L. Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - T. Berger
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, NY 12180 USA
| | - P. A. Breur
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - A. Brown
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E. Brown
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, NY 12180 USA
| | - S. Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - G. Bruno
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R. Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
- Simons Center for Geometry and Physics and C. N. Yang Institute for Theoretical Physics, SUNY, Stony Brook, NY USA
| | - C. Capelli
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J. M. R. Cardoso
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D. Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - B. Cimmino
- Department of Physics “Ettore Pancini”, University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M. Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - D. Coderre
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A. P. Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
- Institute for Subatomic Physics, Utrecht University, Utrecht, Netherlands
| | - J. Conrad
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - J. P. Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - M. P. Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - A. Depoian
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - P. Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - A. Di Giovanni
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R. Di Stefano
- Department of Physics “Ettore Pancini”, University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - S. Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - A. Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G. Eurin
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A. D. Ferella
- Department of Physics and Chemistry, University of L’Aquila, 67100 L’Aquila, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - W. Fulgione
- Department of Physics, INAF-Astrophysical Observatory of Torino, University of Torino and INFN-Torino, 10125 Turin, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - P. Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - R. Gaior
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - A. Gallo Rosso
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - M. Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F. Gao
- Physics Department, Columbia University, New York, NY 10027 USA
| | - L. Grandi
- Department of Physics, Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - M. Garbini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - C. Hasterok
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C. Hils
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K. Hiraide
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
| | - L. Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - E. Hogenbirk
- Nikhef and the University of Amsterdam, Science Park, 1098 XG Amsterdam, The Netherlands
| | - J. Howlett
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M. Iacovacci
- Department of Physics “Ettore Pancini”, University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - Y. Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - F. Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N. Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
| | - S. Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
- Institute for Advanced Research, Nagoya University, Nagoya, Aichi, 464-8601 Japan
| | - M. Kobayashi
- Physics Department, Columbia University, New York, NY 10027 USA
| | - G. Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - A. Kopec
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - H. Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - R. F. Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - L. Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - Q. Lin
- Physics Department, Columbia University, New York, NY 10027 USA
| | - S. Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - F. Lombardi
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
| | - J. A. M. Lopes
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
- Coimbra Polytechnic - ISEC, Coimbra, Portugal
| | - E. López Fune
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - C. Macolino
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J. Mahlstedt
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - L. Manenti
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - A. Manfredini
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F. Marignetti
- Department of Physics “Ettore Pancini”, University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | | | - K. Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
| | - J. Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D. Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S. Mastroianni
- Department of Physics “Ettore Pancini”, University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M. Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - K. Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501 Japan
| | - A. Molinario
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - K. Morå
- Physics Department, Columbia University, New York, NY 10027 USA
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - S. Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
| | - Y. Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - M. Murra
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - J. Naganoma
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L’Aquila, Italy
| | - K. Ni
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - U. Oberlack
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K. Odgers
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, NY 12180 USA
| | - J. Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - B. Pelssers
- Department of Physics, Oskar Klein Centre, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - R. Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J. Pienaar
- Department of Physics, Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - V. Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G. Plante
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J. Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - H. Qiu
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - D. Ramírez García
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S. Reichard
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A. Rocchetti
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - N. Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J. M. F. dos Santos
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
| | - G. Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - N. Šarčević
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M. Scheibelhut
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S. Schindler
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D. Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M. Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L. Scotto Lavina
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M. Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F. Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P. Shagin
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - E. Shockley
- Department of Physics, Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - M. Silva
- Department of Physics, LIBPhys, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H. Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A. Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
| | - C. Therreau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D. Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - F. Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G. Trinchero
- Department of Physics, INAF-Astrophysical Observatory of Torino, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - C. Tunnell
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - M. Vargas
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - G. Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - O. Wack
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - H. Wang
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
| | - Y. Wei
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - C. Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M. Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, 7610001 Israel
| | - D. Wenz
- Institut für Physik and Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J. Westermann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C. Wittweg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - J. Wulf
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - Z. Xu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M. Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205 Japan
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - J. Ye
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - G. Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
- INFN, Sez. di Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, via G. Saragat 1, Edificio C, I-44122, Ferrara (FE), Italy
| | - Y. Zhang
- Physics Department, Columbia University, New York, NY 10027 USA
| | - T. Zhu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J. P. Zopounidis
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| |
Collapse
|
28
|
Aprile E, Aalbers J, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Amaro FD, Andaloro S, Antochi VC, Angelino E, Angevaare JR, Arneodo F, Baudis L, Bauermeister B, Bellagamba L, Benabderrahmane ML, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Coderre D, Colijn AP, Conrad J, Cuenca J, Cussonneau JP, Decowski MP, Depoian A, Di Gangi P, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Ferella AD, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Grandi L, Hils C, Hiraide K, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Joerg F, Kato N, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Liang S, Lindemann S, Lindner M, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Morå K, Moriyama S, Mosbacher Y, Murra M, Naganoma J, Ni K, Oberlack U, Odgers K, Palacio J, Pelssers B, Peres R, Pierre M, Pienaar J, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Dos Santos JMF, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Valerius K, Vargas M, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu Z, Yamashita M, Ye J, Zavattini G, Zhang Y, Zhu T, Zopounidis JP. Search for Coherent Elastic Scattering of Solar ^{8}B Neutrinos in the XENON1T Dark Matter Experiment. Phys Rev Lett 2021; 126:091301. [PMID: 33750173 DOI: 10.1103/physrevlett.126.091301] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 01/17/2021] [Accepted: 01/27/2021] [Indexed: 06/12/2023]
Abstract
We report on a search for nuclear recoil signals from solar ^{8}B neutrinos elastically scattering off xenon nuclei in XENON1T data, lowering the energy threshold from 2.6 to 1.6 keV. We develop a variety of novel techniques to limit the resulting increase in backgrounds near the threshold. No significant ^{8}B neutrinolike excess is found in an exposure of 0.6 t×y. For the first time, we use the nondetection of solar neutrinos to constrain the light yield from 1-2 keV nuclear recoils in liquid xenon, as well as nonstandard neutrino-quark interactions. Finally, we improve upon world-leading constraints on dark matter-nucleus interactions for dark matter masses between 3 and 11 GeV c^{-2} by as much as an order of magnitude.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Aalbers
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Ahmed Maouloud
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Alfonsi
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F D Amaro
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - S Andaloro
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - F Arneodo
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - B Bauermeister
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - A Brown
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E Brown
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - B Cimmino
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - D Coderre
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - J Cuenca
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Depoian
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - A Di Giovanni
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A D Ferella
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Physics Department, Columbia University, New York, New York 10027, USA
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - L Grandi
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Hiraide
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - F Lombardi
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - J Long
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - A Manfredini
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Marignetti
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Mastroianni
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - J Naganoma
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Odgers
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - B Pelssers
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - J Pienaar
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - D Ramírez García
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Reichard
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Scotto Lavina
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - E Shockley
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Therreau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - M Vargas
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - Y Zhang
- Physics Department, Columbia University, New York, New York 10027, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J P Zopounidis
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| |
Collapse
|
29
|
Bagante F, Ruzzenente A, Ratti F, Alexandrescu S, Poultsides G, Weiss M, Popescu I, Aldrighetti L, Guglielmi A, Pawlik T. Parenchymal sparing versus anatomical hepatectomies in patients with multifocal (≥4 tumors) colorectal liver metastasis: Results of an international multi-institutional analysis. Eur J Surg Oncol 2020. [DOI: 10.1016/j.ejso.2020.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Bodas M, Givon A, Peleg K, Abbod N, Bahouth H, Bala M, Becker A, Ben Eli M, Braslavsky A, Grevtsev I, Jeroukhimov I, Karawani M, Kessel B, Klein Y, Lin G, Merin O, Mnouskin Y, Rivkind A, Shaked G, Soffer D, Stein M, Schwartz A, Weiss M. Are casualties from mass-casualty Motor Vehicle Crashes different from casualties of other Motor Vehicle Crashes? Journal of Transport & Health 2020; 19:100928. [DOI: 10.1016/j.jth.2020.100928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2023]
|
31
|
Henes M, Bösmüller H, Neis F, Wallwiener D, Brucker S, Weiss M. Non-invasive-physical-plasma treatment of low- and high-grade cervical intraepithelial neoplasia: a non-invasive and anaesthesia-independent treatment procedure evaluated in a prospective, monocentric clinical trial. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | | | | | - M Weiss
- Natural and Medical Sciences Institute (NMI) at the University of Tübingen
| |
Collapse
|
32
|
Slavin A, Campbell V, Mayo M, Rong H, Zheng X, Ji N, Weiss M, Rusin S, Sharma K, Gollob J, Mainolfi N. 588 Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Baumeister RGH, Wallmichrath J, Weiss M, Baumeister SHC, Frick A. MICROSURGICAL LYMPHATIC VASCULAR GRAFTING AND SECONDARY LIPOSUCTION: RESULTS OF COMBINATION TREATMENT IN SECONDARY LYMPHEDEMA. Lymphology 2020. [DOI: 10.2458/lymph.4653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Surgical treatment of lymphedema with liposuction typically requires subsequent compression therapy. Here we describe an approach where secondary arm lymphedemas are initially treated by autologous lymphatic grafting to bypass the axilla and restore lymphatic flow. In the presence of excess adipose tissue, liposuction is then performed in a second procedure. To assess outcomes, the authors evaluated 28 consecutive adult patients who had undergone secondary liposuction following lymphatic grafting. Arm volumes were measured prior to lymphatic grafting and after the secondary liposuction. The necessity for additional treatment by compression garment and manual lymphatic drainage was assessed prior to lymphatic grafting and after the secondary liposuction following the direct postoperative regimen. The mean arm volumes were reduced significantly (p<0.001) from a mean of 3417±171 (SEM) cm3 prior to lymphatic grafting to 3020±125 cm3 after reconstruction of the lymphatic vascular system and finally to 2516±104 cm3 after the secondary liposuction (SLS). All 28 adult patients underwent continuous compression and manual lymph-drainage (MLD) prior to the reconstructive surgery. All 28 patients were evaluated regarding necessity of any additional therapy more than 6 months after SLS with a median follow up period of 37 months (range, 7-160 months). 18 of 28 patients did not require any supportive therapy beyond 6 months after SLS to maintain the results. Three patients continued to utilize manual lymphatic drainage, 4 used a combination of MLD and compression therapy and 3 used elastic compression therapy (one patient only while at work). These results indicate that microsurgical restoration of lymphatic outflow followed by SLS eliminates the need for additional treatment in more than two thirds of patients.
Collapse
|
34
|
Weiss M, de Masson A, Robin M, Peffault de Latour R, Bagot M, Socié G, Bouaziz JD. Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment. J Eur Acad Dermatol Venereol 2020; 34:e791-e793. [PMID: 32329912 DOI: 10.1111/jdv.16524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Weiss
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - A de Masson
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - M Robin
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - R Peffault de Latour
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - M Bagot
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - G Socié
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - J-D Bouaziz
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| |
Collapse
|
35
|
Baumeister RGH, Wallmichrath J, Weiss M, Baumeister SHC, Frick A. Microsurgical lymphatic vascular grafting and secondary liposuction: Results of combination treatment in secondary lymphedema. Lymphology 2020; 53:38-47. [PMID: 32521129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Surgical treatment of lymphedema with liposuction typically requires subsequent compression therapy. Here we describe an approach where secondary arm lymphedemas are initially treated by autologous lymphatic grafting to bypass the axilla and restore lymphatic flow. In the presence of excess adipose tissue, liposuction is then performed in a second procedure. To assess outcomes, the authors evaluated 28 consecutive adult patients who had undergone secondary liposuction following lymphatic grafting. Arm volumes were measured prior to lymphatic grafting and after the secondary liposuction. The necessity for additional treatment by compression garment and manual lymphatic drainage was assessed prior to lymphatic grafting and after the secondary liposuction following the direct postoperative regimen. The mean arm volumes were reduced significantly (p<0.001) from a mean of 3417± 171 (SEM) cm3 prior to lymphatic grafting to 3020±125 cm3 after reconstruction of the lymphatic vascular system and finally to 2516±104 cm3 after the secondary liposuction (SLS). All 28 adult patients underwent continuous compression and manual lymph-drainage (MLD) prior to the reconstructive surgery. All 28 patients were evaluated regarding necessity of any additional therapy more than 6 months after SLS with a median follow up period of 37 months (range, 7-160 months). 18 of 28 patients did not require any supportive therapy beyond 6 months after SLS to maintain the results. Three patients continued to utilize manual lymphatic drainage, 4 used a combination of MLD and compression therapy and 3 used elastic compression therapy (one patient only while at work). These results indicate that microsurgical restoration of lymphatic outflow followed by SLS eliminates the need for additional treatment in more than two thirds of patients.
Collapse
Affiliation(s)
- R G H Baumeister
- Consultant in Lymphology and Microsurgery Chirurgische Klinik Muenchen Bogenhausen and Urologische Klinik Muenchen Planegg, Munich
| | - J Wallmichrath
- Former Head of the Division of Plastic-, Hand- and Microsurgery, Department of Surgery, Campus Grosshadern, Ludwig-Maximilians University, Munich
- Division of Hand, Plastic and Aesthetic Surgery, University Hospital, LMU Munich, Germany
| | - M Weiss
- Department of Nuclear Medicine, University Hospital, LMU Munich, Germany
| | - S H C Baumeister
- Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA
- Division of Pediatric Hematology-Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA
| | - A Frick
- Division of Hand, Plastic and Aesthetic Surgery, University Hospital, LMU Munich, Germany
| |
Collapse
|
36
|
Jay S, Comar A, Benicio R, Beauvois J, Dutartre D, Daubige G, Li W, Labrosse J, Thomas S, Henry N, Weiss M, Baret F. Scoring Cercospora Leaf Spot on Sugar Beet: Comparison of UGV and UAV Phenotyping Systems. Plant Phenomics 2020; 2020:9452123. [PMID: 33313567 PMCID: PMC7706347 DOI: 10.34133/2020/9452123] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 05/30/2020] [Indexed: 05/19/2023]
Abstract
Selection of sugar beet (Beta vulgaris L.) cultivars that are resistant to Cercospora Leaf Spot (CLS) disease is critical to increase yield. Such selection requires an automatic, fast, and objective method to assess CLS severity on thousands of cultivars in the field. For this purpose, we compare the use of submillimeter scale RGB imagery acquired from an Unmanned Ground Vehicle (UGV) under active illumination and centimeter scale multispectral imagery acquired from an Unmanned Aerial Vehicle (UAV) under passive illumination. Several variables are extracted from the images (spot density and spot size for UGV, green fraction for UGV and UAV) and related to visual scores assessed by an expert. Results show that spot density and green fraction are critical variables to assess low and high CLS severities, respectively, which emphasizes the importance of having submillimeter images to early detect CLS in field conditions. Genotype sensitivity to CLS can then be accurately retrieved based on time integrals of UGV- and UAV-derived scores. While UGV shows the best estimation performance, UAV can show accurate estimates of cultivar sensitivity if the data are properly acquired. Advantages and limitations of UGV, UAV, and visual scoring methods are finally discussed in the perspective of high-throughput phenotyping.
Collapse
Affiliation(s)
- S. Jay
- INRAE, UMR 114 EMMAH, UMT CAPTE, F-84914 Avignon, France
| | - A. Comar
- HIPHEN SAS, 84000 Avignon, France
| | | | | | | | - G. Daubige
- INRAE, UMR 114 EMMAH, UMT CAPTE, F-84914 Avignon, France
| | - W. Li
- HIPHEN SAS, 84000 Avignon, France
| | | | - S. Thomas
- ARVALIS-Institut du végétal, 84000 Avignon, France
| | - N. Henry
- Florimond Desprez, 59242 Capelle-en-Pévèle, France
| | - M. Weiss
- INRAE, UMR 114 EMMAH, UMT CAPTE, F-84914 Avignon, France
| | - F. Baret
- INRAE, UMR 114 EMMAH, UMT CAPTE, F-84914 Avignon, France
| |
Collapse
|
37
|
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR, Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan K, Coltart R, Gee B, Gore M, Farrugia D, Martin-Clavijo A, Marsden J, Price C, Farrugia D, Nathan K, Coltart R, Nathan K, Coltart R. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol 2019; 29:1843-1852. [PMID: 30010756 PMCID: PMC6096737 DOI: 10.1093/annonc/mdy229] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. Results Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). Conclusions Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. Clinical Trial Information ISRCTN 81261306; EudraCT Number: 2006-005505-64
Collapse
Affiliation(s)
- P G Corrie
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
| | - A Marshall
- Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
| | - P D Nathan
- Medical Oncology, Mount Vernon Hospital, Northwood, UK
| | - P Lorigan
- Department of Medical Oncology, Christie Hospital, Manchester, UK
| | - M Gore
- Royal Marsden Hospital NHS Trust, London, UK
| | - S Tahir
- Oncology Research, Broomfield Hospital, Chelmsford, UK
| | - G Faust
- Oncology Department, Leicester Royal Infirmary, Leicester, UK
| | - C G Kelly
- Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne, UK
| | - M Marples
- Leeds Cancer Centre, St James's University Hospital, Leeds, UK
| | - S J Danson
- Weston Park Hospital, Academic Unit of Clinical Oncology, Sheffield, UK
| | - E Marshall
- Cancer & Palliative Care, St. Helen's Hospital, St. Helens, UK
| | - S J Houston
- Oncology Department, Royal Surrey County Hospital, Guildford, UK
| | - R E Board
- Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK
| | - A M Waterston
- Clinical Trials Unit, Beatson WOS Cancer Centre, Glasgow, UK
| | - J P Nobes
- Department of Clinical Oncology, Norfolk & Norwich University Hospital, Norwich, UK
| | - M Harries
- Guy's & St. Thomas' Hospital, Guy's Cancer Centre, London, UK
| | - S Kumar
- Velindre Cancer Centre, Cardiff, UK
| | - A Goodman
- Exeter Oncology Centre, Royal Devon and Exeter Hospital, Exeter, UK
| | - A Dalgleish
- St George's Hospital, Cancer Centre, London, UK
| | | | - S Westwell
- Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK
| | - R Casasola
- Cancer Centre, Ninewells Hospital, Dundee, UK
| | - D Chao
- Royal Free Hospital, London, UK
| | | | - P M Patel
- Academic Unit of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - C H Ottensmeier
- CRUK and NIHR Southampton Experimental Cancer Medicine Centre, Southampton University Hospitals NHS Foundation Trust, Southampton, UK
| | - D Farrugia
- Oncology Centre, Cheltenham General Hospital, Cheltenham, UK
| | - A Humphreys
- Oncology Department, James Cook University Hospital, Middlesbrough, UK
| | - B Eccles
- Oncology Department, Poole Hospital, Dorset, UK
| | - G Young
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - E O Barker
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - C Harman
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - M Weiss
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - K A Myers
- Department of Oncology, University of Oxford, Oxford, UK; Experimental Cancer Medicine Centre, Oxford, UK
| | - A Chhabra
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | | | - J A Dunn
- Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol 2019; 30:2013-2014. [PMID: 31430371 PMCID: PMC6938599 DOI: 10.1093/annonc/mdz237] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
39
|
Weiss M, Bouaziz JD, De Masson A, Robin M, Peffault De Latour R, Bagot M, Socié G. Rémission complète d’une GVH cutanée chronique sclérodermiforme sévère après traitement par IL-2 à faible dose. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Rao A, Shin E, Meyer J, Thompson E, Fu W, Hu C, Fishman E, Weiss M, Wolfgang C, Burkhart R, He J, Kerdsirichariat T, Herman J, Ding K, Narang A. Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image-Guided Radiotherapy (IGRT) for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1923] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
41
|
Sim S, Weiss M, Mendelson J, Estin D, Lustgarten J, Chen Y, Yang C, Danish M, Tiggs D, Olson T. Gamma Knife Thalamotomy of Medication Refractory Tremor Disorders. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Batliner M, Weiss M, Dual SA, Grass B, Meboldt M, Schmid Daners M. Evaluation of a novel flow-controlled syringe infusion pump for precise and continuous drug delivery at low flow rates: a laboratory study. Anaesthesia 2019; 74:1425-1431. [PMID: 31373391 DOI: 10.1111/anae.14784] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/20/2019] [Indexed: 12/25/2022]
Abstract
Syringe infusion pumps are used for the administration of short-acting drugs in anaesthesia and critical care medicine, but are prone to flow irregularities at low flow rates. A flow-controlled syringe infusion pump using an integrated flow sensor for feedback control represents a new approach to overcoming these limitations. This study compares the performance of a prototype flow-controlled syringe pump both at start-up, and during vertical displacement manoeuvres, with that of a standard infusion syringe pump. The novel pump almost completely eliminated delays at start-up and flow irregularities during hydrostatic pressure changes. Related fluctuations in plasma drug concentration were minimised and the known disadvantages of standard syringe infusion pumps currently used in clinical practice were reduced. Besides providing fast start-up to steady-state flow and precise continuous drug delivery at low flow rates during hydrostatic pressure changes, the new pump offers the potential for the development of target-controlled infusion algorithms for short-acting cardiovascular and other drugs.
Collapse
Affiliation(s)
- M Batliner
- Product Development Group Zurich, ETH Zurich, Zurich, Switzerland
| | - M Weiss
- Department of Anaesthesia, University Children's Hospital Zurich, Zurich, Switzerland
| | - S A Dual
- Product Development Group Zurich, ETH Zurich, Zurich, Switzerland
| | - B Grass
- Department of Intensive Care and Neonatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - M Meboldt
- Product Development Group Zurich, ETH Zurich, Zurich, Switzerland
| | - M Schmid Daners
- Product Development Group Zurich, ETH Zurich, Zurich, Switzerland
| |
Collapse
|
43
|
Centurion P, Caballero G, Weiss M. Comment to: "Laser-Assisted Liposuction (LAL) Versus Traditional Liposuction: Systematic Review". Aesthetic Plast Surg 2019; 43:1122-1123. [PMID: 29500605 DOI: 10.1007/s00266-018-1110-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2018] [Accepted: 02/19/2018] [Indexed: 11/24/2022]
Affiliation(s)
- P Centurion
- Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
| | | | | |
Collapse
|
44
|
Kelleher J, Campbell V, Chen J, Gollob J, Ji N, Kamadurai H, Klaus C, Li H, Loh C, McDonald A, Rong H, Rusin S, Sharma K, Vigil D, Walker D, Weiss M, Yuan K, Zhang Y, Mainolfi N. KYM-001, A FIRST-IN-CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88-MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION. Hematol Oncol 2019. [DOI: 10.1002/hon.89_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Kelleher
- Discovery; Kymera Therapeutics; Cambridge United States
| | - V. Campbell
- Discovery; Kymera Therapeutics; Cambridge United States
| | - J. Chen
- Discovery; Kymera Therapeutics; Cambridge United States
| | - J. Gollob
- Discovery; Kymera Therapeutics; Cambridge United States
| | - N. Ji
- Discovery; Kymera Therapeutics; Cambridge United States
| | - H. Kamadurai
- Discovery; Kymera Therapeutics; Cambridge United States
| | - C. Klaus
- Discovery; Kymera Therapeutics; Cambridge United States
| | - H. Li
- Discovery; Kymera Therapeutics; Cambridge United States
| | - C. Loh
- Discovery; Kymera Therapeutics; Cambridge United States
| | - A. McDonald
- Discovery; Kymera Therapeutics; Cambridge United States
| | - H. Rong
- Discovery; Kymera Therapeutics; Cambridge United States
| | - S. Rusin
- Discovery; Kymera Therapeutics; Cambridge United States
| | - K. Sharma
- Discovery; Kymera Therapeutics; Cambridge United States
| | - D. Vigil
- Discovery; Kymera Therapeutics; Cambridge United States
| | - D. Walker
- Discovery; Kymera Therapeutics; Cambridge United States
| | - M. Weiss
- Discovery; Kymera Therapeutics; Cambridge United States
| | - K. Yuan
- Discovery; Kymera Therapeutics; Cambridge United States
| | - Y. Zhang
- Discovery; Kymera Therapeutics; Cambridge United States
| | - N. Mainolfi
- Discovery; Kymera Therapeutics; Cambridge United States
| |
Collapse
|
45
|
Siman-Tov M, Radomislensky I, Marom I, Kapra O, Peleg K, Bahouth H, Becker A, Jeroukhimov I, Karawani I, Kessel B, Klein Y, Lin G, Merin O, Bala M, Mnouskin Y, Rivkind A, Shaked G, Sivak G, Soffer D, Stein M, Weiss M. A nation-wide study on the prevalence of non-collision injuries occurring during use of public buses. Journal of Transport & Health 2019; 13:164-169. [DOI: 10.1016/j.jth.2019.03.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2023]
|
46
|
Abraham JE, Vallier AL, Qian W, Machin A, Grybowicz L, Thomas S, Weiss M, Harvey C, McAdam K, Hughes-Davies L, Roberts A, Provenzano E, Pinilla K, Roylance R, Copson E, Armstrong A, McMurtry E, Tischkowitz M, Earl HM. Abstract OT3-01-02: PARTNERING / PARTNER : Phase II sub-study to establish if the addition of combinations of new agents (olaparib, cell cycle and immune checkpoint inhibitors) can improve the rate of pathological complete response (pCR) and minimal residual disease (MRD) in triple negative breast cancer (TNBC) and / or germline BRCA mutated (gBRCAm) patients with evidence of residual disease after PARTNER therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
In patients with TNBC, following standard neoadjuvant chemotherapy, residual disease (RD) is correlated with poor prognosis and 50% relapse within 5 years [1]. PARTNER is a neoadjuvant clinical trial which randomises TNBC and gBRCAm patients to carboplatin and paclitaxel +/- olaparib followed by anthracycline-based chemotherapy. Patients with RD after neoadjuvant treatment in this trial also face poorer survival outcomes, due to the paucity of treatment options. PARTNERING, develops a new strategy using novel agent combinations as an alternative pathway for patients with RD within the PARTNER trial.
Methods: PARTNERING is a phase II open label, sub-study with a two-stage Simon design with biomarker guided treatment cohorts open only to patients in the PARTNER trial. A maximum of 15 patients will be included in each cohort. Patients with RD > 10% tumour cellularity (TC) on biopsy after neoadjuvant therapy will be eligible. Patients who have no tumour cells or < 10% TC, and those with progressive disease will be excluded. Allocation of patients into the cohorts will be based on tumour infiltrating lymphocytes (TILs) expression either on diagnostic or post treatment biopsy. Patients with tumours with TILs score ≤20% are considered “non-immunogenic” They will be stratified according to HRD status and allocated to receive a cell cycle checkpoint inhibitor + olaparib. Patients with a TILs score >20% are considered “immunogenic” and will be allocated to receive an immune checkpoint inhibitor with olaparib or a cell cycle checkpoint inhibitor.
Primary outcome measure is pCR / MRD rate at surgery after the administration of 2 cycles / 8 weeks of a combination of new agents. The rate of conversion to pCR/MRD will be correlated with TC, TILs, BRCA and homologous recombination deficiency (HRD) status, Ki67% and previous olaparib treatment.
Progress: The PARTNERING pathway in the PARTNER trial will be open late 2018.
Citation Format: Abraham JE, Vallier A-L, Qian W, Machin A, Grybowicz L, Thomas S, Weiss M, Harvey C, McAdam K, Hughes-Davies L, Roberts A, Provenzano E, Pinilla K, Roylance R, Copson E, Armstrong A, McMurtry E, Tischkowitz M, Earl HM. PARTNERING / PARTNER : Phase II sub-study to establish if the addition of combinations of new agents (olaparib, cell cycle and immune checkpoint inhibitors) can improve the rate of pathological complete response (pCR) and minimal residual disease (MRD) in triple negative breast cancer (TNBC) and / or germline BRCA mutated (gBRCAm) patients with evidence of residual disease after PARTNER therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-01-02.
Collapse
Affiliation(s)
- JE Abraham
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A-L Vallier
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - W Qian
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Machin
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - L Grybowicz
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - S Thomas
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - M Weiss
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - C Harvey
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - K McAdam
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - L Hughes-Davies
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Roberts
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E Provenzano
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - K Pinilla
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - R Roylance
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E Copson
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Armstrong
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E McMurtry
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - M Tischkowitz
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - HM Earl
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| |
Collapse
|
47
|
Abraham J, Vallier AL, Qian W, Machin A, Grybowicz L, Thomas S, Weiss M, Harvey C, McAdam K, Hughes-Davies L, Roberts A, Roylance R, Copson E, Pinilla K, Armstrong A, Provenzano E, Tischkowitz M, McMurty E, Earl H. Abstract OT3-03-03: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: No specific targeted therapies are available for Triple Negative Breast Cancers (TNBC), an aggressive and diverse subgroup. The basal TNBC sub-group share some phenotypic and molecular similarities with germline BRCA (gBRCA) tumours. In gBRCA patients, and potentially other homologous recombination deficiencies, these already compromised pathways may allow drugs called PARP inhibitors (Olaparib) to work more effectively. Aims: To establish if the addition of olaparib to neoadjuvant platinum based chemotherapy for basal TNBC and/or gBRCA breast cancer is safe and improves efficacy (pathological complete response (pCR)).
Methods: Trial design: 3-stage open label randomised phase II/III trial of neoadjuvant paclitaxel and carboplatin +/- olaparib, followed by clinicians' choice of anthracycline regimen. Stage 1 and 2: Randomisation (1:1:1) to either control (3 weekly carboplatin AUC5/weekly paclitaxel 80mg/m2 for 4 cycles) or one of two research arms with the same chemotherapy regimen but with two different schedules of olaparib 150mg BD for 12 days. Stage 3: Patients are randomised (1:1) to either control arm or to the research arm selected in stage 2. End-points: Stage 1: Safety; Stage 2: Schedule selection using pCR rate and completion rate of olaparib using a “pick-the-winner” design. Stage 3: pCR rate. Enrichment design is applied with an overall significance level 0.05(α) and 80% power. A total of 527 patients will be included to detect an absolute improvement of 15% (all patients) and 20% (gBRCA patients) by adding olaparib to platinum based chemotherapy.
Trial Progress: PARTNER has been recruiting in UK since 27th May 2016. IDSMC recommended to continue the trial without change after reviewing the Stage 1 safety data. The recruitment of stage 2 was completed in April 2018 and results to be reviewed by the IDSMC in early 2019. The trial is open and enrolling patients to national and international sites.
Citation Format: Abraham J, Vallier A-L, Qian W, Machin A, Grybowicz L, Thomas S, Weiss M, Harvey C, McAdam K, Hughes-Davies L, Roberts A, Roylance R, Copson E, Pinilla K, Armstrong A, Provenzano E, Tischkowitz M, McMurty E, Earl H. PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-03-03.
Collapse
Affiliation(s)
- J Abraham
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A-L Vallier
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - W Qian
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Machin
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - L Grybowicz
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - S Thomas
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - M Weiss
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - C Harvey
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - K McAdam
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - L Hughes-Davies
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Roberts
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - R Roylance
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E Copson
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - K Pinilla
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - A Armstrong
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E Provenzano
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - M Tischkowitz
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - E McMurty
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| | - H Earl
- University of Cambridge, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University College London, London, United Kingdom; University of Southampton, Southampton, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Astra Zenecca, Macclesfield, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom
| |
Collapse
|
48
|
Hoffmann SM, Kappel D, Fech A, Enderle MD, Weiss M, Hahn M, Brucker SY, Kraemer B. Thermal effects of a novel electrosurgical device for focused preparation in breast surgery tested in a specified porcine tissue ex vivo breast model using infrared measurement. Arch Gynecol Obstet 2019; 299:835-840. [PMID: 30607596 DOI: 10.1007/s00404-018-5024-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 12/14/2018] [Indexed: 11/25/2022]
Abstract
PURPOSE This article investigates the qualities and thermal effects of a novel electrosurgical device (PT) which has been designed by ERBE Elektromedizin GmbH, Germany, for the preparation of critical locations such as in skin-sparing or nipple-sparing techniques and compares it to a standard device (SD) in a porcine ex vivo breast model using an heat map generated by infrared thermography. METHODS In total, 42 abdominal wall specimens of porcine tissue consisting of the skin and the underlying subcutaneous and muscle layer were alternately dissected using one of the devices and pre-settings. During the preparation with the two devices, the epicutaneous temperature was measured by an infrared camera (VarioCam, Jenoptik, Germany) and the maximum temperature as well as the slope of the temperature rise was analysed. RESULTS The use of PT shows significantly lower values for [Formula: see text] compared to SD. This effect was independent from the chosen mode. Using the same instrument in different modes, the use of AutoCut mode showed a significant reduction of [Formula: see text] at all indicated time points (SD: p < 0.0001 and PT: p < 0.0001). In summary, the combination of AutoCut + PT showed the lowest rise in temperature, whereas the combination of DryCut + SD led to the highest rise in temperature. The temperature difference between these two settings was 13.84 °C, which means a possible temperature reduction of 67% can be achieved by the right choice of device and its tailored mode. CONCLUSIONS The novel PT shows a significant reduction in epicutaneous temperature and a significant reduction of the slope of temperature rise most probably by a more focused application of energy compared to SD.
Collapse
Affiliation(s)
- S M Hoffmann
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany.
| | - D Kappel
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany
| | - A Fech
- ERBE Elektromedizin GmbH, Waldhoernlestr. 17, 72070, Tübingen, Germany
| | - M D Enderle
- ERBE Elektromedizin GmbH, Waldhoernlestr. 17, 72070, Tübingen, Germany
| | - M Weiss
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany
| | - M Hahn
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany
| | - S Y Brucker
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany
| | - B Kraemer
- Department of Obstetrics and Gynecology, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany
| |
Collapse
|
49
|
Weiss M, Hainke K, Grund S, Gerlach K, Mülling CKW, Geiger SM. Does the range of motion in the bovine interphalangeal joints change with flooring condition? A pilot study using biplane high-speed fluoroscopic kinematography. J Dairy Sci 2018; 102:1443-1456. [PMID: 30591344 DOI: 10.3168/jds.2018-14844] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 11/03/2018] [Indexed: 11/19/2022]
Abstract
This study had 2 objectives. The first objective was to investigate motion patterns and the range of motion of the bovine proximal and distal interphalangeal joints on concrete during the stance phase. The second objective was to determine whether the range of motion and the locomotive stability of the interphalangeal joints differ on concrete and 3 different commercially available rubber mats (Karera, Kura, and Pedikura; Kraiburg Elastik GmbH & Co. KG, Tittmoning, Germany). Biplane high-speed fluoroscopic kinematography (72 ± 2.5 kV and 112.5 ± 12.5 mA, refresh rate 500 frames per second, shutter 0.5 ms) was applied to record 1 stance phase of the right forelimb of 2 Holstein Friesian heifers (15 mo old, 440 ± 10 kg; ± standard deviation) on each flooring. Three-dimensional digital animations were generated with a marker-supported manual animation technique based on the recordings and computer tomographic bone models. The mean maximum range of motion of each of the 4 interphalangeal joints in terms of flexion/extension, abduction/adduction, and internal/external rotation were calculated as well as the mean number of local extrema as a measure of stability during the stance phase. The main degree of freedom in all interphalangeal joints was flexion and extension with a range of motion of 17.7 to 25.9°. The second largest degree of freedom differed between abduction/adduction (7.7-10.0°) and internal/external rotation (6.5-9.6°) depending on the joint. Remarkably, although smaller, these extrasagittal directions still contribute to the overall motion to a considerable degree. In addition, the interphalangeal joints of the lateral digit showed a tendency to move less during the stance phase than their medial counterparts. Comparing concrete to the rubber mats, the interphalangeal joints tend to have to cover a larger range of motion on concrete with the exception of the distal interphalangeal joint in terms of flexion/extension. The unyielding surface of concrete seems to force the flexible parts of the animal-ground-interaction into extended motion. Furthermore, there tends to be more instability in all 3 degrees of freedom in all 4 joints on concrete, implying a greater effort of the soft tissues to achieve a balanced motion. Detailed biomechanical research contributes to the development of adequate flooring systems by evaluating the mechanical strain on claws and joints and working toward lameness prevention and thus animal welfare.
Collapse
Affiliation(s)
- M Weiss
- Institute of Veterinary Anatomy, Histology and Embryology, Leipzig University, D-04103 Leipzig, Germany
| | - K Hainke
- Institute of Veterinary Anatomy, Histology and Embryology, Leipzig University, D-04103 Leipzig, Germany
| | - S Grund
- Institute of Veterinary Anatomy, Histology and Embryology, Leipzig University, D-04103 Leipzig, Germany
| | - K Gerlach
- Department for Horses, Faculty of Veterinary Medicine, Leipzig University, D-04103 Leipzig, Germany
| | - C K W Mülling
- Institute of Veterinary Anatomy, Histology and Embryology, Leipzig University, D-04103 Leipzig, Germany
| | - S M Geiger
- Institute of Veterinary Anatomy, Histology and Embryology, Leipzig University, D-04103 Leipzig, Germany; Institute of Topographic Anatomy, University of Veterinary Medicine Vienna, A-1210 Vienna.
| |
Collapse
|
50
|
Siman-Tov M, Radomislensky I, Peleg K, Bahouth H, Becker A, Jeroukhimov I, Karawani I, Kessel B, Klein Y, Lin G, Merin O, Bala M, Mnouskin Y, Rivkind A, Shaked G, Sivak G, Soffer D, Stein M, Weiss M. A look at electric bike casualties: Do they differ from the mechanical bicycle? Journal of Transport & Health 2018; 11:176-182. [DOI: 10.1016/j.jth.2018.10.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2023]
|